STOCK TITAN

Beyeotech's 2.44M-share stake in Oculis (OCS) equals 4.14% of float

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Oculis Holding AG reporting persons filed an amended Schedule 13G/A stating that Beyeotech directly holds 2,436,902 Ordinary Shares, representing 4.14% of the outstanding ordinary shares based on February 13, 2026 and a reported share count of 58,932,987 Ordinary Shares.

The statement names the related filers—BVCF IV, L.P., Beyeotech, BVCF IV GP, Ltd. and Zhi Yang—and explains their ownership and control relationships, including that GP is the general partner of the Fund and Mr. Zhi Yang is sole shareholder/director of GP.

Positive

  • None.

Negative

  • None.

Insights

Filing clarifies ownership and control links among related entities.

The filing documents that Beyeotech directly holds 2,436,902 shares (~4.14%) of the company's ordinary shares as of February 13, 2026. It notes the chain of control: GP is general partner of the Fund and Mr. Zhi Yang is sole shareholder and director of GP.

This structure explains why multiple affiliated entities file jointly under Rule 13d-1(k)(1). Subsequent disclosures would show any material changes in percent ownership or voting power.

Disclosure signals an under-5% institutional stake without immediate dilution impact.

The reported position of 2,436,902 shares equals 4.14% of 58,932,987 issued and outstanding shares (as of February 13, 2026), placing the holder below the 5% ownership threshold noted in Item 5.

Because the stake is below 5%, the filing is routine; any future material purchases or sales would be reported in amendments or Forms 4/13D as required.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Notes to Rows 6, 8 and 9: See Item 2(a) below. Notes to Row 11: Based on 58,932,987 Ordinary Shares issued and outstanding of the Issuer as of February 13, 2026.


SCHEDULE 13G



BVCF IV, L.P.
Signature:By: BVCF IV GP, Ltd., its general partner /s/ Zhi Yang
Name/Title:Zhi Yang/Director
Date:03/27/2026
BEYEOTECH
Signature:/s/ Bernard Yang Feng
Name/Title:Bernard Yang Feng/Director
Date:03/27/2026
BVCF IV GP, Ltd.
Signature:/s/ Zhi Yang
Name/Title:Zhi Yang/Director
Date:03/27/2026
Zhi Yang
Signature:/s/ Zhi Yang
Name/Title:Zhi Yang
Date:03/27/2026
Exhibit Information

Joint Filing Agreement dated April 28, 2023 https://www.sec.gov/Archives/edgar/data/1761158/000119312523131200/d499516dex991.htm

FAQ

What stake does Beyeotech hold in Oculis Holding (OCS)?

Beyeotech directly holds 2,436,902 Ordinary Shares, equal to 4.14% of the company's shares based on February 13, 2026 and a stated total of 58,932,987 outstanding ordinary shares.

Who are the reporting persons on the Schedule 13G/A for OCS?

The filing is by BVCF IV, L.P., Beyeotech, BVCF IV GP, Ltd. and Zhi Yang, who executed a joint filing agreement dated April 28, 2023 and describe their control relationships in Item 2(a).

Does the filing say who has voting or dispositive power?

The cover rows show 0 sole voting/dispositive power and 2,436,902 shared voting and dispositive power for the reporting group, with explanatory notes referenced in the Item 2(a) ownership description.

Is the reported position over the 5% disclosure threshold?

No. The reported position is 4.14% of outstanding shares as of February 13, 2026, which the filing classifies under Item 5 as ownership of 5 percent or less of a class.

Where can I find the joint filing agreement referenced in the Schedule 13G/A?

The filing cites a Joint Filing Agreement dated April 28, 2023 and provides an exhibit link to the SEC archive where that agreement is posted as part of the exhibits to the filing.
Oculis Holding

NASDAQ:OCS

View OCS Stock Overview

OCS Rankings

OCS Latest News

OCS Latest SEC Filings

OCS Stock Data

1.45B
50.00M
Biotechnology
Healthcare
Link
Switzerland
Zug